Recently Featured

FDA’s OCE PFDD Program Enhances Collaboration for Cancer Patient Outcomes

April 27, 2026
The FDA’s Oncology Center of Excellence (OCE) has launched the Patient-Focused Drug Development (PFDD) program, which aims to foster collaboration between FDA centers and external stakeholders dedicated to improving patient outcomes in cancer populations. This initiative is pivotal as it aligns regulatory processes with the real-world experiences and needs of patients, ensuring that drug development…

Generic Drug User Fee Amendments Enhance Industry Landscape

April 27, 2026
The Generic Drug User Fee Amendments (GDUFA) have been updated to streamline the approval process for generic drugs, significantly impacting the pharmaceutical landscape. These amendments introduce a revised fee structure aimed at increasing the efficiency of the FDA’s review process, thereby expediting the entry of affordable generic medications into the market. In the context of…

Gerresheimer & Milliken Partner to Advance Performance & Protection With LeneX UltraGuard Technology

April 26, 2026
Gerresheimer has announced a strategic partnership with Milliken & Company to implement LeneX™ UltraGuard®, an advanced additive technology aimed at enhancing polymer performance in pharmaceutical applications. This collaboration builds upon previous successes between Bormioli Pharma S.p.A., a subsidiary of Gerresheimer, and Milliken, showcasing a commitment to high-value solutions for global pharmaceutical clients. By integrating LeneX™…

Precautionary Recall of Blood Pressure Medication After Manufacturing Error

April 26, 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a precautionary recall for a specific batch of blood pressure medication following a significant manufacturing error. This directive instructs pharmacy and healthcare professionals to cease the distribution of the affected batch and to return all remaining stock to suppliers. Such recalls are critical in maintaining…

Ongoing Cases